Méningococcie
Canadian Immunization Guide: Evergreen Edition
Evergreen edition presents information on the immunizing agents available in Canada and their use in the prevention of communicable diseases.
Guide canadien d'immunisation : Edition évolutive
Le présent Guide (édition évolutive) contient des renseignements sur les agents immunisants disponibles au Canada et sur leur utilisation en vue de prévenir les maladies transmissibles.
The Use of Bivalent Factor H Binding Protein Meningococcal Serogroup B (MenB-fHBP) Vaccine for the Prevention of Meningococcal B Disease
Utilisation du vaccin bivalent dirigé contre la protéine de liaison au facteur H (MenB-fHBP) pour la prévention de l’infection à méningocoque du sérogroupe B
Mise à jour sur la vaccination contre la méningococcie invasive chez les enfants et les adolescents canadiens
Invasive meningococcal disease (IMD) is serious, often resulting in fulminant sepsis or meningitis. IMD in Canada is primarily attributable to serogroups B and C. There are routine programs for serogroup C vaccine at 12 months of age, with some jurisdictions routinely providing additional earlier doses. Adolescents routinely receive a booster dose of serogroup C vaccine or of a quadrivalent (serogroups A, C, W and Y) vaccine. Serogroup B vaccines are not recommended for routine use pending further data on the efficacy and duration of protection from the available vaccine. However, children at increased risk for IMD should start immunization for serogroups B and C as soon as possible, assuming that they are at least 2 months of age.
Update on invasive meningococcal vaccination for Canadian children and youth
Invasive meningococcal disease (IMD) is serious, often resulting in fulminant sepsis or meningitis. IMD in Canada is primarily attributable to serogroups B and C. There are routine programs for serogroup C vaccine at 12 months of age, with some jurisdictions routinely providing additional earlier doses. Adolescents routinely receive a booster dose of serogroup C vaccine or of a quadrivalent (serogroups A, C, W and Y) vaccine. Serogroup B vaccines are not recommended for routine use pending further data on the efficacy and duration of protection from the available vaccine. However, children at increased risk for IMD should start immunization for serogroups B and C as soon as possible, assuming that they are at least 2 months of age.
Augmentation des infections invasives à Neisseria meningitidis de sérogroupe W au Canada de 2009 à 2016
La prévalence de la méningococcie à MenW augmente au Canada et est associée à une augmentation des cas attribuables au complexe clonal ST-11 émergent, qui a maintenant été identifié dans cinq provinces canadiennes. Il semble plus courant chez les patients âgés que le complexe clonal ST-22 traditionnel, plus répandu chez les jeunes patients.
Immunization for meningococcal serogroup B: What does the practitioner need to know?
Most invasive meningococcal disease in Canada is now caused by serogroup B organisms. A vaccine directed against this serogroup (4CMenB) is newly licensed in Canada. It is hoped that this document will be useful to clinicians when faced with questions from parents.
Increase in Neisseria meningitidis serogroup W invasive disease in Canada: 2009–2016
MenW meningococcal disease is growing in prevalence in Canada and is associated with an increase in the emerging ST-11 CC. This emerging clonal complex has now been identified in five provinces in Canada. It appears to be more common in older patients than the traditional ST-22 CC, which occurs more often in younger patients.
La vaccination contre le méningocoque du sérogroupe B : ce que le praticien doit savoir
Au Canada, la plupart des méningococcies invasives sont désormais causées par des organismes du sérogroupe B. Un vaccin conçu contre ce sérogroupe (4CMenB) vient d'être homologué au Canada. Le présent document peut être utile aux cliniciens qui devront répondre aux questions des parents.